The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

BENZYDAMINE     3-(1-benzylindazol-3-yl)oxy- N,N-dimethyl...

Synonyms: SureCN26172, BBL009932, CAS-132-69-4, AKOS005530662, BRN 0896536, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of BENZYDAMINE


High impact information on BENZYDAMINE

  • We investigated the metabolism of benzydamine (BZD) in controls as well as patients with severe FMO3 deficiency and found evidence of markedly reduced N-oxygenation capacity both in serum and urine samples [6].
  • Benzydamine inhibits monocyte migration and MAPK activation induced by chemotactic agonists [7].
  • ERK1/12 activation in response to chemoattractants was 89-98% inhibited by a 100 microm concentration of benzydamine with an IC50 of 30 microm [7].
  • 5. Under the same experimental conditions, pretreatment with 100 microm benzydamine caused a 75-89% inhibition of p38 activation (IC50 25 microm) [7].
  • 2. Benzydamine inhibited monocyte chemotaxis in response to three classes of chemoattractants: the prototypic CC-chemokine CCL2 (MCP-1), the microbial product fMLP and the complement cascade component C5a [7].

Chemical compound and disease context of BENZYDAMINE


Biological context of BENZYDAMINE


Anatomical context of BENZYDAMINE


Associations of BENZYDAMINE with other chemical compounds


Gene context of BENZYDAMINE


Analytical, diagnostic and therapeutic context of BENZYDAMINE


  1. Benzydamine cream for the treatment of post-herpetic neuralgia: minimum duration of treatment periods in a cross-over trial. McQuay, H.J., Carroll, D., Moxon, A., Glynn, C.J., Moore, R.A. Pain (1990) [Pubmed]
  2. Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. Cheng, K.K., Chang, A.M., Yuen, M.P. Eur. J. Cancer (2004) [Pubmed]
  3. Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. Epstein, J.B., Stevenson-Moore, P., Jackson, S., Mohamed, J.H., Spinelli, J.J. Int. J. Radiat. Oncol. Biol. Phys. (1989) [Pubmed]
  4. Interstitial cystitis. Observations on diagnosis and on treatment with anti-inflammatory drugs, particularly benzydamine. Walsh, A. Eur. Urol. (1977) [Pubmed]
  5. Double-blind study of benzydamine hydrochloride, a new treatment for sore throat. Wethington, J.F. Clinical therapeutics. (1985) [Pubmed]
  6. Benzydamine metabolism in vivo is impaired in patients with deficiency of flavin-containing monooxygenase 3. Mayatepek, E., Flock, B., Zschocke, J. Pharmacogenetics (2004) [Pubmed]
  7. Benzydamine inhibits monocyte migration and MAPK activation induced by chemotactic agonists. Riboldi, E., Frascaroli, G., Transidico, P., Luini, W., Bernasconi, S., Mancini, F., Guglielmotti, A., Milanese, C., Pinza, M., Sozzani, S., Mantovani, A. Br. J. Pharmacol. (2003) [Pubmed]
  8. Benzydamine: an alternative nonsteroidal anti-inflammatory drug in patients with nimesulide-induced urticaria. Nettis, E., Di Paola, R., Napoli, G., Ferrannini, A., Tursi, A. Allergy (2002) [Pubmed]
  9. Dexpanthenol pastille and benzydamine hydrochloride spray for the prevention of post-operative sore throat. Gulhas, N., Canpolat, H., Cicek, M., Yologlu, S., Togal, T., Durmus, M., Ozcan Ersoy, M. Acta anaesthesiologica Scandinavica (2007) [Pubmed]
  10. Several therapies may prevent or reduce the severity of oral mucositis associated with cancer treatment. Sutherland, S. Evidence-based dentistry (2006) [Pubmed]
  11. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management. Epstein, J.B., Schubert, M.M. Oncology (Williston Park, N.Y.) (2003) [Pubmed]
  12. Nimesulide for the treatment of painful inflammatory process in the ear, nose and throat areas: a double-blind controlled study with benzydamine. Milvio, C. J. Int. Med. Res. (1984) [Pubmed]
  13. Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Störmer, E., Roots, I., Brockmöller, J. British journal of clinical pharmacology. (2000) [Pubmed]
  14. Use of ultrasound to enhance percutaneous absorption of benzydamine. Benson, H.A., McElnay, J.C., Harland, R. Physical therapy. (1989) [Pubmed]
  15. Biotransformation of benzydamine by microsomes and precision-cut slices prepared from cattle liver. Santi, A., Anfossi, P., Coldham, N.G., Capolongo, F., Sauer, M.J., Montesissa, C. Xenobiotica (2002) [Pubmed]
  16. Benzydamine protection in a mouse model of endotoxemia. Guglielmotti, A., Aquilini, L., Rosignoli, M.T., Landolfi, C., Soldo, L., Coletta, I., Pinza, M. Inflamm. Res. (1997) [Pubmed]
  17. Effects of benzydamine on the lipolytic system of fat cells. Dinnendahl, V., Peters, H.D., Schönhöfer, P.S. Biochem. Pharmacol. (1976) [Pubmed]
  18. Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo scaling of benzydamine clearance. Fisher, M.B., Yoon, K., Vaughn, M.L., Strelevitz, T.J., Foti, R.S. Drug Metab. Dispos. (2002) [Pubmed]
  19. Photodegradation of benzydamine: phototoxicity of an isolated photoproduct on erythrocytes. Vargas, F., Rivas, C., Machado, R., Sarabia, Z. Journal of pharmaceutical sciences. (1993) [Pubmed]
  20. Paf-acether-induced death in mice: involvement of arachidonate metabolites and beta-adrenoceptors. Criscuoli, M., Subissi, A. Br. J. Pharmacol. (1987) [Pubmed]
  21. High-performance liquid chromatography assay for the measurement of benzydamine hydrochloride in topical pharmaceutical preparations. Benson, H.A., McElnay, J.C. J. Chromatogr. (1987) [Pubmed]
  22. In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Lang, D.H., Rettie, A.E. British journal of clinical pharmacology. (2000) [Pubmed]
  23. Oral mucositis. Scully, C., Sonis, S., Diz, P.D. Oral diseases. (2006) [Pubmed]
  24. Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Moncada, S., Needleman, P., Bunting, S., Vane, J.R. Prostaglandins (1976) [Pubmed]
  25. Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine. Sironi, M., Pozzi, P., Polentarutti, N., Benigni, F., Coletta, I., Guglielmotti, A., Milanese, C., Ghezzi, P., Vecchi, A., Pinza, M., Mantovani, A. Cytokine (1996) [Pubmed]
  26. Benzydamine inhibits the release of tumor necrosis factor-alpha and monocyte chemotactic protein-1 by Candida albicans-stimulated human peripheral blood cells. Sironi, M., Milanese, C., Vecchi, A., Polenzani, L., Guglielmotti, A., Coletta, I., Landolfi, C., Soldo, L., Mantovani, A., Pinza, M. Int. J. Clin. Lab. Res. (1997) [Pubmed]
  27. An assay of flavin-containing monooxygenase activity with benzydamine N-oxidation. Kawaji, A., Ohara, K., Takabatake, E. Anal. Biochem. (1993) [Pubmed]
  28. Determination of benzydamine and its N-oxide in biological fluids by high-performance liquid chromatography. Baldock, G.A., Brodie, R.R., Chasseaud, L.F., Taylor, T. J. Chromatogr. (1990) [Pubmed]
  29. Amperometric biosensor based on monoamine oxidase (MAO) immobilized in sol-gel film for benzydamine determination in pharmaceuticals. de Jesus, D.S., Couto, C.M., Araújo, A.N., Montenegro, M.C. Journal of pharmaceutical and biomedical analysis. (2003) [Pubmed]
WikiGenes - Universities